Methylprednisolone therapy for short-term prevention of SUNCT syndrome

Cephalalgia. 2010 Jun;30(6):735-9. doi: 10.1111/j.1468-2982.2009.01971.x. Epub 2010 Feb 1.

Abstract

Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is characterized by severe and frequent daily pain attacks causing transient physical disability for the patients during the headache period. Currently there is no option for abortive treatment of the attacks, mainly due to the short-lived nature and frequency of the repeated headaches, while highly efficacious therapy is also unavailable for short-term prevention. We report rapidly suppressed headache attacks with orally administered methylprednisolone in eight headache periods of three patients with idiopathic, episodic SUNCT syndrome. The remission was maintained until the period was over in all cases. Although the mechanism of methylprednisolone action is unclear, it is probably based on the anti-inflammatory effects of the drug.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Humans
  • Male
  • Methylprednisolone / therapeutic use*
  • Middle Aged
  • Neuroprotective Agents / therapeutic use*
  • SUNCT Syndrome / physiopathology
  • SUNCT Syndrome / prevention & control*

Substances

  • Neuroprotective Agents
  • Methylprednisolone